Detail of "33433-82-8"

Reference

Teratogenesis of calcium valproate in rabbits

Teratogenesis of calcium valproate in rabbits. Petrere, Judith A.; Anderson, John A.; Sakowski, Raymond; Fitzgerald, James E.; De la Iglesia, Felix (Warner-Lambert/Parke-Davis, Ann Arbor, MI 48105, USA). Teratology, 34(3), 263-9 (English) 1986. CODEN: TJADAB. ISSN: 0040-3709. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The teratogenic potential of Ca valproate [33433-82-8] was detd. in rabbits. Groups of Dutch-belted rabbits were given oral doses of 50, 150, or 350 mg/kg on days 6-18 of gestation. A ref. group was given 350 mg Na valproate [1069-66-5]/kg and control groups were untreated or given vehicle alone. Animals were obsd. daily and body wts. were recorded on gestation days 0, 6, 13, 18, and 30. Litter and fetal parameters were evaluated following uterotomies on day 30. No drug-related clin. signs or deaths occurred. Postimplantation loss and the incidence of malformed vertebrae and ribs, rudimentary or absent pollices, and extra vertebrae and ribs were increased at 350 mg/kg with both salts of valproic acid. At the 150-mg/kg dose level, Ca valproate markedly increased the incidence of supernumerary ribs. No teratogenic or embryotoxic effects were seen with Ca valproate at 50 mg/kg. Thus, the Na and Ca salts of valproic acid exhibit teratogenic potential in rabbits.

Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt

Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt. Glazko, Anthony J.; Chang, Tsun; Daftsios, A. C.; Eiseman, Irene; Smith, Thomas C.; Buchanan, Robert A. (Warner-Lambert/Parke-Davis Pharm. Res., Ann Arbor, MI 48104, USA). Ther. Drug Monit., 5(4), 409-17 (English) 1983. CODEN: TDMODV. ISSN: 0163-4356. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Calcium valproate [33433-82-8] was formulated into tablets contg.There are some reagents with their cas registry numbers 99-66-1 and 1069-66-5 are used in this study. the equiv. of 250 mg valproic acid (VPA) [99-66-1]. The bioequivalence of this prepn. (Valontin) was studied in 12 normal adult males in parallel with other products contg. VPA (Depakene capsules) and Na valproate (Depakene syrup) [1069-66-5]. Each subject received a single 500-mg oral dose of each product at 2-wk intervals in a randomized 3-way crossover study. VPA was detd. in blood and urine specimens collected over extended times. Peak plasma levels were attained on the av. within 30 min with the syrup, 1.13 h with the capsules, and 1.38 h with the tablets. There were no significant differences in the peak plasma levels attained or in the plasma half-lives of VPA and areas under the time-concn. curves. The plasma level curves appeared to be biexponential, with terminal half-lives that averaged 16.6 h. One subject had a remarkably long drug half-life (28-38 h) after each of the 3 doses, indicating the possibility of genetic differences. 9He urinary excretion of VPA in most subjects ran parallel to the plasma levels and could not be detected 96 h after dosing; however, the subject with the long plasma half-life continued to excrete VPA in his urine for at least 2 addnl. days. The mean recovery of VPA in 6-day urine represented 12-14% of the dose and was 5.5-27.9% in different individuals. There were no significant differences between the 3 formulations in the pattern of urinary excretion. .